Resistant Hypertension Course Scientific Board’s view on Medtronic’s press release about SYMPLICITY HTN-3

Medtronic, Inc. announced yesterday that its U.S. trial in renal denervation for treatment-resistant hypertension, SYMPLICITY HTN-3, has met its primary safety endpoint, while it did not reach its primary efficacy endpoint, defined as a difference of, at least, 15 mmHg office systolic blood pressure, between sham and active renal denervation groups.

The RHC Board shares its point of view:

Final 3-year report of the Symplicity HTN-1 study is published online in the Lancet

The Symplicity HTN-1 (n=150) was the first multicenter, proof-of-concept and safety study for patients with resistant arterial hypertension (mean age 57 years) undergoing catheter-based renal denervation. Patients in the Symplicity HTN-1 study were heavily medicated, taking an average of five antihypertensive drugs, and were still poorly controlled (office blood pressure 175/98mmHg). The primary endpoint was peri-procedural and safety of the treatment (n=45) after 1 and 12 month published in 2009 at the Lancet (1).

4 questions to Sebastian A. Potthoff

Sebastian Ewen asks questions to Sebastian A. Potthoff, first author of The “resistant hypertension team”: focus on a multidisciplinary approach to hypertension article published in EuroIntervention Journal Supplement on Resistant Hypertension Treatments, May 2013.


When the Resistant Hypertension Course website was created eighteen months ago, we announced that…

“This is not a website, it's an open debating forum..."

to initiate a debate and change the way we learn; we need openness, real experiences and YOUR opinion. Experience the web, watch the videos, read the articles and express your thoughts and comments, this web platform is yours! If you're ready for a sharing/learning (r)evolution, then let's evolve together!